Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) FCF Margin: 2013-2017

Historic FCF Margin for Tvardi Therapeutics (TVRD) over the last 2 years, with Mar 2017 value amounting to -2,375.85%.

  • Tvardi Therapeutics' FCF Margin rose 13858129.00% to -2,375.85% in Q1 2017 from the same period last year, while for Mar 2017 it was -1,742.07%, marking a year-over-year decrease of 105656.00%. This contributed to the annual value of -55,927.91% for FY2016, which is 5536262.00% down from last year.
  • According to the latest figures from Q1 2017, Tvardi Therapeutics' FCF Margin is -2,375.85%, which was up 83.80% from -14,662.03% recorded in Q2 2016.
  • In the past 5 years, Tvardi Therapeutics' FCF Margin registered a high of -320.33% during Q3 2015, and its lowest value of -140,957.14% during Q1 2016.
  • Moreover, its 3-year median value for FCF Margin was -1,724.43% (2015), whereas its average is -26,645.96%.
  • In the last 5 years, Tvardi Therapeutics' FCF Margin crashed by 13,988,414bps in 2016 and then spiked by 13,858,129bps in 2017.
  • Tvardi Therapeutics' FCF Margin (Quarterly) stood at -520.55% in 2013, then slumped by 11,829bps to -638.84% in 2014, then skyrocketed by 8,047bps to -320.33% in 2015, then plummeted by 1,417,461bps to -14,662.03% in 2016, then surged by 13,858,129bps to -2,375.85% in 2017.
  • Its last three reported values are -2,375.85% in Q1 2017, -14,662.03% for Q2 2016, and -140,957.14% during Q1 2016.